Appraisals - ASAR & FAR

20/09/2024

Equality and Health Impact Assessment: galsulfase 155

20/09/2024

Equality and Health Impact Assessment: miglustat 371

20/09/2024

Evidence Status Report: miglustat 371

20/09/2024

Evidence Status Report: galsulfase (Naglazyme)155

10/07/2024

Final Recommendation: cytisine 3708

26/06/2024

Evidence Summary Report: cytisine 3708

26/06/2024

Equality and Health Impact Assessment : cytisine 3708

16/05/2024

Final Recommendation: opicapone (Ongentys) 5285

01/02/2021

Appraisal Report: opicapone (Ongentys) 911

01/05/2024

Appraisal Report: opicapone (Ongentys®) 5285

29/04/2024

Final Recommendation: trifarotene (Aklief) 3153 FAR

29/04/2024

Appraisal Report: trifarotene (Aklief) 3153

02/05/2024

Evidence summary report alglucosidase alfa (Myozyme)

03/04/2024

Equality Impact Assessment: trifarotene (Aklief) 3153

18/07/2023

Appraisal report: emtricitabine/tenofovir alafenamide (Descovy®) 2566

18/05/2023

Safety alert for dexmedetomidine (AWTTC Ref 661)

15/05/2023

Equality Impact Assessment levodopa carbidopa entacapone

27/04/2023

Final Recommendation: levodopa carbidopa entacapone (Lecigon) 4871

06/04/2023

Appraisal Report: levodopa carbidopa entacapone (Lecigon) 4871

08/08/2019

Final Recommendation: tenofovir (Viread) 1880